

**TABLE 187: RELAPSE**

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Afdhal et al., 2014 ION-1	1	(6) SOF12 + LDV12	1	214	0%
		(7) SOF24 + LDV24	1	217	0%
		(10) SOF12 + LDV12 + RBV12	0	217	0%
		(11) SOF24 + LDV24 + RBV24	0	217	0%
Dieterich et al., 2014-1	1	(42) SIM12 PR24-48 RGT	5	53	9%
Feld et al., 2014 SAPPHIRE-I	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	7	463	2%
Ferenci et al., 2014 PEARL-III	1b	(14) PAR/RIT12 + OMB12 + DAS12	0	209	0%
Ferenci et al., 2014 PEARL-IV	1a	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	1	100	1%
Fried et al., 2013 PILLAR	1	(1) PR48	11	77	14%
		(42) SIM12 PR24-48 RGT	6	77	8%
Gane et al., 2013-3 ELECTRON	1	(3) SOF12 + RBV12	8	25	32%
Gane et al., 2014-1 ELECTRON	1	(10) SOF12 + LDV12 + RBV12	0	25	0%
Jacobson et al., 2014 QUEST-1	1	(1) PR48	18	130	14%
		(42) SIM12 PR24-48 RGT	21	264	8%
Jacobson et al., 2011 ADVANCE	1	(1) PR48	64	361	18%
		(32) T12 PR24-48 RGT q8	27	363	7%
Kohli et al., 2015	1	(6) SOF12 + LDV12	0	20	0%
Kowdley et al., 2013 ATOMIC	1	(40) SOF12 + PR12	2	52	4%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Kowdley et al., 2014 ION-3	1	(6) SOF12 + LDV12	3	216	1%
		(8) SOF8 + LDV8	11	215	5%
		(9) SOF8 + LDV8 + RBV8	9	216	4%
Kumada et al., 2014	1b	(17) DCV24 + ASU24	11	135	8%
Lalezari et al. et al., 2015	1	(15) PAR/RIT12 + OMB12 + DAS12 + RBV12	0	38	0%
Lawitz et al., 2013 NEUTRINO	1+4+5+6	(40) SOF12 + PR12	28	327	9%
Lawitz et al., 2013 FISSION	2+3	(3) SOF12 + RBV12	74	256	29%
		(70) PR24	46	243	19%
Lawitz et al., 2013-1 PROTON	1	(1) PR48	0	26	0%
		(41) SOF12 PR24-48 RGT	1	47	2%
Lawitz et al., 2013-2 PROTON	2+3	(40) SOF12 + PR12	0	25	0%
Lawitz et al., 2015-1 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	1	29	3%
Lawitz et al., 2015-1 C-WORTHY		(59) GRZ18 + ELB18 (50 mg q.d.)	2	31	6%
Lawitz et al., 2015-1 C-WORTHY		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	2	31	6%
Lawitz et al., 2015-1 C-WORTHY		(65) GRZ18 + ELB18 (50 mg q.d.) + RBV18	0	32	0%
Lawitz et al., 2014 LONESTAR	1	(6) SOF12 + LDV12	0	19	0%
		(8) SOF8 + LDV8	1	20	5%
		(9) SOF8 + LDV8 + RBV8	0	21	0%
Manns et al., 2014 QUEST-2	1	(1) PR48	21	134	16%
		(42) SIM12 PR24-48 RGT	30	257	12%
Manns et al., 2014 HALLMARK-DUAL	1b	(17) DCV24 + ASU24	5	205	2%
Marcellin et al., 2011	1	(32) T12 PR24-48 RGT q8	5	82	6%
		(33) T12 PR24-48 RGT q12	4	79	5%
Mizokami et al. et al., 2015	1	(6) SOF12 + LDV12	0	83	0%
		(10) SOF12 + LDV12 + RBV12	1	83	1%
Molina et al., 2015-1 PHOTON-2	1	(4) SOF24 + RBV24	14	112	13%
Molina et al., 2015-2 PHOTON-2	2	(3) SOF12 + RBV12	1	19	5%
Molina et al., 2015-3 PHOTON-2	3	(4) SOF24 + RBV24	4	57	7%
Molina et al., 2015-4 PHOTON-2	4	(4) SOF24 + RBV24	5	31	16%
Muir et al. et al., 2015 UNITY-2	1	(25) DCV12 + ASU12 + BEC12 + RBV12	0	55	0%
		(26) DCV12 + ASU12 + BEC12	4	57	7%
Nelson D. et al., 2015 ALLY-3	3	(19) DCV12 + SOF12	9	100	9%
Omata et al., 2014	2	(3) SOF12 + RBV12	2	90	2%

AUTHOR, YEAR, STUDY NAME	GENOTYPE	TREATMENT	n	N	%
Osinusi et al., 2013 SPARE-1	1	(4) SOF24 + RBV24	0	10	0%
Osinusi et al., 2013 SPARE-2	1	(4) SOF24 + RBV24	7	25	28%
		(71) SOF24 + RBV (low dose) 24	10	25	40%
Osinusi et al., 2015	1	(6) SOF12 + LDV12	1	50	2%
Pearlman et al., 2015	1	(5) SIM12 + SOF12	0	22	0%
		(40) SOF12 + PR12	1	10	10%
Poordad et al., 2011 SPRINT2	1	(1) PR48	39	363	11%
		(46) B24 PR28-48 RGT	24	368	7%
Poordad et al. et al., 2015 UNITY-1	1	(26) DCV12 + ASU12 + BEC12	15	312	5%
Rodriguez-Torres et al., 2015	1+2+3+4	(40) SOF12 + PR12	1	23	4%
Ruane et al., 2014	2+3+4	(3) SOF12 + RBV12	2	13	15%
		(4) SOF24 + RBV24	0	14	0%
Sulkowski et al., 2015-1 C-WORTHY	1	(23) GRZ12 + ELB12 + RBV12	2	85	2%
		(57) GRZ12 + ELB12 (50 mg q.d.)	1	44	2%
		(61) GRZ8 + ELB8 (50 mg q.d.) + RBV8	5	30	17%
Sulkowski et al., 2015-2 C-WORTHY	1	(57) GRZ12 + ELB12 (50 mg q.d.)	0	30	0%
		(63) GRZ12 + ELB12 (50 mg q.d.) + RBV12	1	29	3%
Sulkowski et al., 2014-2	1	(4) SOF24 + RBV24	25	115	22%
Sulkowski et al., 2014	1	(19) DCV12 + SOF12	0	41	0%
Sulkowski et al., 2013-1	1	(1) PR48	0	6	0%
		(39) T12 PR48 q8	1	7	14%
Sulkowski et al., 2013-2	1	(1) PR48	2	8	25%
		(39) T12 PR48 q8	0	15	0%
Sulkowski et al., 2013	1	(1) PR48	1	34	3%
		(50) B44 PR48	2	64	3%
Zeuzem et al., 2015-1 C-EDGE	1+4+6	(22) GRZ12 + ELB12	10	288	3%
Zeuzem et al., 2015-2 C-EDGE		(22) GRZ12 + ELB12	0	18	0%
Zeuzem et al., 2015-3 C-EDGE		(22) GRZ12 + ELB12	2	10	20%

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; b.i.d. = twice daily; CrI = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.  
Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.